AZD4045

A Modular, Phase I/​II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.
Trial status

Not yet accepting

Phase
Phase 1/2
Enrollment
101
Last Updated

Participating Centers

There are 6 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Interleukin-2
  • Daratumumab
  • AZD4045

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not yet accepting

Module 1: AZD4045 + Daratumumab + Aldesleukin

Not yet accepting

Module 1: AZD4045 Monotherapy

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.